CRBP news

Corbus Pharmaceuticals reported positive interim results for its periportal restricted CB1 inverse agonist CRB-701 for obesity, with a 5% weight loss at 12 weeks and a favorable safety profile. The Phase 2 monotherapy study is scheduled to commence in the first half of 2027.

Corbus reported CRB-913 achieved a mean weight loss of 5% at 60 mg, supporting its potential as a novel oral obesity treatment. The shares are set to open higher following this trial milestone.

Corbus Pharmaceuticals secured FDA clearance for the Phase 3 TEMPO-1 study of CRB-701 in oropharyngeal cancer and announced leadership appointments to advance its clinical pipeline toward 2026 milestones.

Crescent Biopharma Inc. entered an underwriting agreement with Jefferies LLC and TD Securities to sell 8,094,793 shares and relevant warrants. This capital raise allows the Cayman Islands company to proceed with its planned public offering.

Corbus Pharmaceuticals Holdings, Inc. entered into an employment agreement with Leonardo Viana Nicacio, M.D. to serve as Chief Medical Officer effective August 3, 2026. The appointment of key personnel is a routine corporate governance matter.

Corbus Pharmaceuticals announced updated Phase 1/2 data showing CRB-701 demonstrated robust activity in second-line oropharyngeal and cervical cancers with confirmed response rates of 42.9% and 34.4% respectively, with a favorable safety profile. The company plans to initiate a registrational TEMPO-…

Corbus Pharmaceuticals has entered into an employment agreement with Nishant Saxena to serve as Chief Business Officer, effective May 21, 2026, with an annual base salary of $470,000. The appointment reflects the company's leadership expansion in its business development and strategy functions.